Current status of stem cell therapy: opportunities and limitations

Rusu, Elena; Necula, Laura; Neagu, Ana Iulia; Alecu, Mihail; Stan, Cristian; Albulescu, Radu; Tănase, Cristiana

doi:10.3906/biy-1506-95

Cited by 12 publications

(5 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[51][52][53] Although some stem cell-loaded hydrogels have demonstrated the capability to promote bone regeneration in animal models, 25,54,55 these strategies are affected by limited cell sources, low cell viability, or controversial therapeutic effects. 56,57 We constructed a cell-free SDF-1α-loaded injectable osteogenic hydrogel simply by mixing SDF-1α, SN, and GelMA pre-polymer. According to a previous study, 58 the degree of GelMA hydrogel methacrylation was ~53.8% when 1.25% w/v MA was added during the synthetic process.…”

Section: Discussionmentioning

confidence: 99%

<p>Nano-Silicate-Reinforced and SDF-1α-Loaded Gelatin-Methacryloyl Hydrogel for Bone Tissue Engineering</p>

Shi

Mulatibieke

et al. 2020

IJN

View full text Add to dashboard Cite

Autologous bone grafts are the gold standard for treating bone defects. However, limited bone supply and morbidity at the donor site restrict its extensive use. Therefore, developing bone graft materials as an alternative to autologous grafts has gained considerable attention. Injectable hydrogels endowed with osteogenic potential have the ability to fill irregular bone defects using minimally invasive procedures and have thus been attracting researchers' attention. However, from a clinical perspective, most fabrication methods employed for the current injectable osteogenic hydrogels are difficult and inconvenient. In the current study, we fabricated an injectable osteogenic hydrogel using a simple and convenient strategy. Materials and Methods: Gelatin-methacryloyl (GelMA) pre-polymer was synthetized. Nano silicate (SN) and stromal cell-derived factor-1 alpha (SDF-1α) were introduced into the pre-polymer to achieve injectability, controlled release property, excellent osteogenic ability, and efficient stem cell homing. Results: The GelMA-SN-SDF-1α demonstrated excellent injectability via a 17-G needle at room temperature. The loaded SDF-1α exhibited a long-term controlled release pattern and efficiently stimulated MSC migration and homing. The GelMA-SN-SDF-1α hydrogel amplified cell spreading, migration, osteogenic-related biomarker expression, and matrix mineralization. The GelMA-SN-SDF-1α hydrogel filled critical-sized calvaria defects in rats and demonstrated excellent bone regeneration ability, as assessed using micro-CT scanning and histomorphometric staining. Conclusion: The GelMA-SN-SDF-1α hydrogel provides a simple and convenient strategy for the fabrication of injectable osteogenic graft materials.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Nano-Silicate-Reinforced and SDF-1α-Loaded Gelatin-Methacryloyl Hydrogel for Bone Tissue Engineering</p>

Shi

Mulatibieke

et al. 2020

IJN

View full text Add to dashboard Cite

show abstract

“…Due to various limitations of using pluripotent embryonic SCs (ESCs) as a treatment option, such as ethical considerations, teratoma development, long-term possibility of carcinogenesis, and potential immunological rejection of transplanted SC [ 89 ], novel strategies of ESCs use are being intensively explored. In 2017, Kim et al reported on the potential use of human ESC (hESC)-derived multipotent mesenchymal SCs (M-MSC) in IC/BPS, with evidence for long-term safety (6 months after transplantation).…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome

et al. 2021

View full text Add to dashboard Cite

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a multifactorial, chronic bladder disorder with limited therapeutic options currently available. The present review provides an extensive overview of therapeutic approaches used in in vitro, ex vivo, and in vivo experimental models of IC/BPS. Publications were identified by electronic search of three online databases. Data were extracted for study design, type of treatment, main findings, and outcome, as well as for methodological quality and the reporting of measures to avoid bias. A total of 100 full-text articles were included. The majority of identified articles evaluated therapeutic agents currently recommended to treat IC/BPS by the American Urological Association guidelines (21%) and therapeutic agents currently approved to treat other diseases (11%). More recently published articles assessed therapeutic approaches using stem cells (11%) and plant-derived agents (10%), while novel potential drug targets identified were proteinase-activated (6%) and purinergic (4%) receptors, transient receptor potential channels (3%), microRNAs (2%), and activation of the cannabinoid system (7%). Our results show that the reported methodological quality of animal studies could be substantially improved, and measures to avoid bias should be more consistently reported in order to increase the value of preclinical research in IC/BPS for potential translation to a clinical setting.

show abstract

“…Hence, alternative materials with improved performance need to be identified to scale up production before release to the industry. Sourcing of iPSCs and their reproducibility are additional limiting factors [ 137 , 138 ]. Since the fluidic system requires very precise extraction and injection of compounds, an automated fluid handling system is required [ 139 ].…”

Section: Challenges and Future Perspectivementioning

confidence: 99%

Breakthroughs and Applications of Organ-on-a-Chip Technology

Koyilot¹,

Natarajan²,

Hunt

et al. 2022

Cells

View full text Add to dashboard Cite

Organ-on-a-chip (OOAC) is an emerging technology based on microfluid platforms and in vitro cell culture that has a promising future in the healthcare industry. The numerous advantages of OOAC over conventional systems make it highly popular. The chip is an innovative combination of novel technologies, including lab-on-a-chip, microfluidics, biomaterials, and tissue engineering. This paper begins by analyzing the need for the development of OOAC followed by a brief introduction to the technology. Later sections discuss and review the various types of OOACs and the fabrication materials used. The implementation of artificial intelligence in the system makes it more advanced, thereby helping to provide a more accurate diagnosis as well as convenient data management. We introduce selected OOAC projects, including applications to organ/disease modelling, pharmacology, personalized medicine, and dentistry. Finally, we point out certain challenges that need to be surmounted in order to further develop and upgrade the current systems.

show abstract

Current status of stem cell therapy: opportunities and limitations

Cited by 12 publications

References 143 publications

<p>Nano-Silicate-Reinforced and SDF-1α-Loaded Gelatin-Methacryloyl Hydrogel for Bone Tissue Engineering</p>

<p>Nano-Silicate-Reinforced and SDF-1α-Loaded Gelatin-Methacryloyl Hydrogel for Bone Tissue Engineering</p>

A Systematic Review of Therapeutic Approaches Used in Experimental Models of Interstitial Cystitis/Bladder Pain Syndrome

Breakthroughs and Applications of Organ-on-a-Chip Technology

Contact Info

Product

Resources

About